ImmunoGen, Inc.
IMGNDelisted Feb 12, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000855654
ImmunoGen, Inc. was delisted on Feb 12, 2024; its insiders filed their last Form 4 on Feb 12, 2024; 327 institutions reported holding it in 13F filings for Q4 2023, worth $7.54B in total; Maverick Capital was the only superinvestor holding it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 327
- Q4 2023, +52 vs. previous quarter
- 13F value
- $7.54B
- Reported value at the end of Q4 2023
- Superinvestors holding
- 1
- At the end of Q4 2023
Superinvestors holding IMGN, Q4 2023
1 superinvestor reports holding ImmunoGen, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Latest insider trades
Open-market purchases and sales by ImmunoGen, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 6, 2024 (view filing) | Feb 5 | 1 day | Coen Stacy AnnSVP & CHIEF BUSINESS OFFICER | SSale | −4.58K | $29.30 | −$134.3K | −5.9%73.3K after | 10b5-1 |
| Feb 6, 2024 (view filing) | Feb 5 | 1 day | Wingrove TheresaSVP OF REGULATORY AFFAIRS | SSale | −12.0K | $29.30 | −$352.4K | −36.4%21.0K after | 10b5-1 |
| Feb 6, 2024 (view filing) | Feb 5 | 1 day | Enyedy Mark JCHIEF EXECUTIVE OFFICER | SSale | −20.1K | $29.28 | −$588.7K | −3.3%584.4K after | 10b5-1 |
| Feb 6, 2024 (view filing) | Feb 5 | 1 day | Lentini ReneeVP & PRIN ACCTG OFFICER | SSale | −2.63K | $29.30 | −$77.1K | −15.2%14.7K after | 10b5-1 |
| Jan 18, 2024 (view filing) | Jan 16 | 2 days | Wingrove TheresaSVP OF REGULATORY AFFAIRS | SSale | −187.7K | $29.64 | −$5.56M | −98.2%3.43K after | 10b5-1 |
| Dec 27, 2023 (view filing) | Dec 26 | 1 day | Lentini ReneeVP & PRIN ACCTG OFFICER | SSale | −6.55K | $29.74 | −$194.7K | −43.7%8.45K after | 10b5-1 |
| Dec 19, 2023 (view filing) | Dec 15 | 4 days | Wingrove TheresaSVP OF REGULATORY AFFAIRS | SSale | −117.4K | $29.40 | −$3.45M | −97.7%2.81K after | 10b5-1 |
| Dec 5, 2023 (view filing) | Nov 30 | 5 daysLate | Coen Stacy AnnSVP & CHIEF BUSINESS OFFICER | SSale | −3.83K | $29.20 | −$111.7K | −10.4%33.1K after | 10b5-1 |
| Dec 5, 2023 (view filing) | Nov 30 | 5 daysLate | Peterson KristineDirector | SSale | −20.0K | $28.90 | −$578.0K | −100.0%0 after | 10b5-1 |
| Dec 1, 2023 (view filing) | Nov 29-30 | 2 days | Wingrove TheresaSVP OF REGULATORY AFFAIRS | SSale | −171.2K | $28.46 | −$4.87M | −98.4%2.81K after | 2 lots10b5-1 |
Top 10 13F holders, Q4 2023
The largest institutional positions in ImmunoGen, Inc. at the end of Q4 2023; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 25,466,950 | $755.1M | 0.02% | +984,795+4.0% | Added |
| Ra Capital Management, L.P. | 23,750,601 | $704.2M | 11.00% | +10,428,313+78.3% | Added |
| BlackRock Inc. | 21,824,392 | $647.1M | 0.02% | +1,550,533+7.6% | Added |
| Redmile Group, LLC | 16,423,922 | $487.0M | 17.42% | −1,079,495−6.2% | Reduced |
| Janus Henderson Group PLC | 11,043,986 | $327.5M | 0.20% | −6,640,830−37.6% | Reduced |
| State Street Corp | 8,075,671 | $239.4M | 0.01% | −1,476,181−15.5% | Reduced |
| Fairmount Funds Management LLC | 5,929,592 | $175.8M | 18.58% | 00.0% | Unchanged |
| Pentwater Capital Management LP | 5,662,500 | $167.9M | 3.15% | +5,662,500 | New |
| Norges Bank | 5,539,334 | $164.2M | 0.03% | +3,484,245+169.5% | Added |
| Geode Capital Management, LLC | 5,382,875 | $159.6M | 0.02% | +482,900+9.9% | Added |